Bessemer Group
ENTA icon

Bessemer Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Bessemer Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-78
Closed -$4K – 1648
2015
Q2 		$4K Buy
+78
New +$3.03K ﹤0.01% 1384

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Bessemer Group's ENTA Position: Q3 2015 in Review

Bessemer Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2015, closing a stake of 78 shares — an estimated $4K sold.

Bessemer Group first reported a position in ENTA in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 144 funds tracked by Wall St. Rank hold ENTA as of Q3 2015.

  • Bessemer Group reported no remaining Enanta Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Bessemer Group sold 78 Enanta Pharmaceuticals shares in Q3 2015, an estimated $4K.
  • Bessemer Group first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Bessemer Group's Enanta Pharmaceuticals position peaked at $4K in Q2 2015.
  • 144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2015.

Based on Bessemer Group's 13F filing for Q3 2015, filed 16 Nov 2015.